Abbott Laboratories (NYSE:ABT) is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. On October 15, 2025, ABT reported earnings per share (EPS) of $1.30, matching the estimated EPS. The company generated revenue of approximately $11.37 billion, slightly below the estimated $11.39 billion.
The company's third-quarter sales increased by 6.9%, reaching $11.37 billion, as highlighted by Proactive Investors. This growth was driven by strong performance in Abbott's medical devices and diagnostics sectors, despite a normalization in COVID-19 testing-related revenue. Organic sales rose by 5.5%, or 7.5% when excluding COVID-19 testing-related revenue.
Abbott's operating margin was reported at 18.1% of sales, with an adjusted operating margin of 23%, marking a 40 basis point increase. The company's GAAP diluted EPS for the quarter stood at $0.94, while the adjusted diluted EPS was $1.30. This marks an increase from the $1.21 per share reported in the same quarter last year.
CEO Robert Ford emphasized the company's consistent, high-quality performance, attributing it to their differentiated product pipeline. Abbott has reaffirmed its full-year guidance, indicating confidence in its ongoing business strategy and market position. The company's price-to-earnings (P/E) ratio is approximately 16.07, reflecting the market's valuation of its earnings.
Abbott's financial metrics, such as a debt-to-equity ratio of approximately 0.27 and a current ratio of around 1.82, suggest a strong financial position. The company's enterprise value to sales ratio is around 5.36, providing insight into its valuation relative to its sales. Abbott's earnings yield is about 6.22%, offering a perspective on its earnings relative to its share price.
